99 related articles for article (PubMed ID: 9219827)
21. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
[TBL] [Abstract][Full Text] [Related]
22. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
23. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Nishimura MI; Avichezer D; Custer MC; Lee CS; Chen C; Parkhurst MR; Diamond RA; Robbins PF; Schwartzentruber DJ; Rosenberg SA
Cancer Res; 1999 Dec; 59(24):6230-8. PubMed ID: 10626817
[TBL] [Abstract][Full Text] [Related]
24. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
[TBL] [Abstract][Full Text] [Related]
25. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
26. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
27. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.
Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP
Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618
[TBL] [Abstract][Full Text] [Related]
28. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.
Matsuda M; Salazar F; Petersson M; Masucci G; Hansson J; Pisa P; Zhang QJ; Masucci MG; Kiessling R
J Exp Med; 1994 Dec; 180(6):2371-6. PubMed ID: 7964510
[TBL] [Abstract][Full Text] [Related]
30. Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer.
Kono K; Ichihara F; Iizuka H; Sekikawa T; Matsumoto Y
Int J Cancer; 1997 Jun; 71(6):978-81. PubMed ID: 9185700
[TBL] [Abstract][Full Text] [Related]
31. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
32. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma.
Mackensen A; Ferradini L; Carcelain G; Triebel F; Faure F; Viel S; Hercend T
Cancer Res; 1993 Aug; 53(15):3569-73. PubMed ID: 8339262
[TBL] [Abstract][Full Text] [Related]
33. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells.
Halliday GM; Patel A; Hunt MJ; Tefany FJ; Barnetson RS
World J Surg; 1995; 19(3):352-8. PubMed ID: 7638987
[TBL] [Abstract][Full Text] [Related]
34. In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.
Derré L; Bruyninx M; Baumgaertner P; Devevre E; Corthesy P; Touvrey C; Mahnke YD; Pircher H; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2007 Aug; 179(4):2368-79. PubMed ID: 17675498
[TBL] [Abstract][Full Text] [Related]
35. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
36. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors.
Tao J; Li Y; Liu YQ; Li L; Liu J; Shen X; Shen GX; Tu YT
Br J Dermatol; 2008 Jan; 158(1):88-94. PubMed ID: 17999701
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
[TBL] [Abstract][Full Text] [Related]
38. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
39. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
40. CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.
Somasundaram R; Robbins P; Moonka D; Loh E; Marincola F; Patel A; Guerry D; Herlyn D
Int J Cancer; 2000 Jan; 85(2):253-9. PubMed ID: 10629086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
